Roche Holding Ltd. (ROG) Given a CHF 260 Price Target at Morgan Stanley
Roche Holding Ltd. (VTX:ROG) has been assigned a CHF 260 target price by analysts at Morgan Stanley in a report issued on Friday. The firm currently has a “neutral” rating on the healthcare company’s stock.
Several other equities research analysts also recently issued reports on ROG. Barclays PLC set a CHF 305 price objective on shares of Roche Holding and gave the stock a “buy” rating in a research report on Tuesday, June 13th. Goldman Sachs Group, Inc. (The) set a CHF 335 price target on shares of Roche Holding and gave the company a “buy” rating in a research report on Thursday, June 15th. Jefferies Group LLC set a CHF 285 price target on shares of Roche Holding and gave the company a “buy” rating in a research report on Friday, June 16th. BNP Paribas set a CHF 250 price target on shares of Roche Holding and gave the company a “neutral” rating in a research report on Tuesday, June 20th. Finally, J P Morgan Chase & Co reiterated a “buy” rating on shares of Roche Holding in a research report on Tuesday, June 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of CHF 267.73.
Roche Holding (ROG) traded up 0.12% during trading on Friday, reaching CHK 248.00. The company’s stock had a trading volume of 557,806 shares. Roche Holding has a 52-week low of CHK 218.30 and a 52-week high of CHK 273.00. The firm’s 50-day moving average is CHK 244.39 and its 200-day moving average is CHK 251.55. The stock has a market cap of CHK 211.61 billion and a P/E ratio of 22.02.
ILLEGAL ACTIVITY WARNING: “Roche Holding Ltd. (ROG) Given a CHF 260 Price Target at Morgan Stanley” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/06/roche-holding-ltd-rog-given-a-chf-260-price-target-at-morgan-stanley.html.
Roche Holding Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.